PRODUCT SUMMARY

1. NAME OF THE MEDICINAL PRODUCT Amoxil® Paediatric Suspension

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Amoxil Paediatric Suspension contains 125 mg amoxycillin per 1.25 ml dose The amoxycillin is present as the trihydrate.

3. PHARMACEUTICAL FORM

Amoxil Paediatric Suspension: citrus flavoured suspension. Presented as powder in bottles for preparing 20 ml.

4. CLINICAL PARTICULARS 4.1. Therapeutic Indications

Treatment of Infection: Amoxil is a broad spectrum antibiotic indicated for the treatment of commonly occurring bacterial infections such as:

Upper respiratory tract infections Otitis media

Acute and chronic bronchitis Chronic bronchial sepsis Lobar and bronchopneumonia Cystitis, urethritis, pyelonephritis Bacteriuria in pregnancy

Gynaecological infections including puerperal sepsis and septic abortion

Gonorrhoea

Peritonitis

Intra-abdominal sepsis Septicaemia Bacterial endocarditis Typhoid and paratyphoid fever Skin and soft tissue infections Osteomyelitis

Dental abscess (as an adjunct to surgical management)

In children with urinary tract infection the need for investigation should be considered.

Prophylaxis of endocarditis: Amoxil may be used for the prevention of bacteraemia, associated with procedures such as dental extraction, in patients at risk of developing bacterial endocarditis.

Consideration should be given to official local guidance (e.g. national requirements) on the appropriate use of antibacterial agents. Susceptibility of the causative organism to the treatment should be tested (if possible), although the therapy may be initiated before the results are available.

4.2 Posology and Method of Administration

Treatment of Infection:

Adult dosage (including elderly patients):

Oral:

Standard adult dosage: 250 mg three times daily, increasing to 500 mg three times daily for more severe infections.

High dosage therapy (maximum recommended oral dosage 6 g daily in divided doses): A dosage of 3 g twice daily is recommended in appropriate cases for the treatment of severe or recurrent purulent infection of the respiratory tract.

Short course therapy: Simple acute urinary tract infection: two 3 g doses with 10-12 hours between the doses. Dental abscess: two 3 g doses with 8 hours between the doses. Gonorrhoea: single 3 g dose.

Children weighing <40kg:

The daily dosage for children is 40 - 90 mg/kg/day in two to three divided doses* (not exceeding 3 g/day) depending on the indication, severity of the disease and the susceptibility of the pathogen (see special dosage recommendations below and sections 4.4, 5.1 and 5.2).

* PK/PD data indicate that dosing three times daily is associated with enhanced efficacy, thus twice daily dosing is only recommended when the dose is in the upper range.

Children weighing more than 40 kg should be given the usual adult dosage.

Special dosage recommendation Tonsillitis: 50 mg/kg/day in two divided doses.

Acute otitis media: In areas with high prevalence of pneumococci with reduced susceptibility to penicillins, dosage regimens should be guided by national/local recommendations. In severe or recurrent acute otitis media, especially where compliance may be a problem, 750 mg twice a day for two

days may be used as an alternative course of treatment in children aged 3 to 10 years.

Early Lyme disease (isolated erythema migrans): 50 mg/kg/day in three divided doses, over 14-21days.

Dosage in impaired renal function:

The dose should be reduced in patients with severe renal function impairment. In patients with a creatinine clearance of less than 30 ml/min an increase in the dosage interval and a reduction in the total daily dose is recommended (see section 4.4 and 5.2):

Glomerular filtration rate >30ml/min No adjustment necessary.

Glomerular filtration rate 10-30ml/min: Amoxicillin. max. 500mg b.d Glomerular filtration rate <10ml/min: Amoxicillin. max. 500mg/day

Renal impairment in children under 40 kg:

Creatinine clearance ml/min	Dose	Interval between administration
> 30	Usual dose	No adjustment necessary
10 - 30	Usual dose	12 h (corresponding to 2/3 of the dose)
< 10	Usual dose	24 h (corresponding to 1/3 of the dose)

Amoxil Paediatric Suspension is recommended for children under six months of age.

CONDITION		ADULTS’ DOSAGE (INCLUDING ELDERLY)	CHILDREN'S DOSAGE (< 40 kg)	NOTES
Dental procedures: prophylaxis for patients undergoing extraction, scaling or surgery involving gingival tissues and who	Patient not having general anaesthetic.	3 g ‘Amoxil’ orally, 1 hour before procedure. A second dose may be given 6 hours later, if considered necessary.	50 mg amoxicillin/kg body weight given as a single dose one hour preceding the surgical procedure	Note 1. If prophylaxis with ‘Amoxil’ is given twice within one month, emergence of resistant streptococci
have not received a penicillin in the previous month. (N.B. Patients with prosthetic heart valves should be referred to hospital - see below).	Patient having general anaesthetic: if oral antibiotics considered to be appropriate.	Initially 3 g ‘Amoxil’ orally 4 hours prior to anaesthesia, followed by 3 g orally (or 1 g IV or IM if oral dose not tolerated) as soon as possible after the operation.		is unlikely to be a problem. Alternative antibiotics are recommended if more frequent prophylaxis is required, or if the patient has received a course of treatment
	Patient having general anaesthetic: if oral antibiotics not appropriate.	1 g ‘Amoxil’ IV or IM immediately before induction; with 500 mg orally, 6 hours later.		with a penicillin during the previous month. Note 2 To minimise pain on injection, ‘Amoxil’ may be given as two injections of 500 mg dissolved in sterile 1% lidocaine solution (see Administration).
Dental procedures: patients for whom referral to hospital is recommended: a)    Patients to be given a general anaesthetic who have been given a penicillin in the previous month. b)    Patients to be given a general anaesthetic who have a prosthetic heart valve. c)    Patients who have had one or more attacks of endocarditis.		Initially: 1 g ‘Amoxil’ IV or IM with 120 mg gentamicin IV or IM immediately prior to anaesthesia (if given) or 15 minutes prior to dental procedure. Followed by (6 hours later): 500 mg ‘Amoxil’ orally.	50 mg amoxicillin/kg body weight given as a single dose one hour preceding the surgical procedure	See Note 2. Note 3. ‘Amoxil’ and gentamicin should not be mixed in the same syringe. Note 4. Please consult the appropriate data sheet for full prescribing information on gentamicin.
Genitourinary Surgery or Instrumentation: prophylaxis for patients who have no urinary tract infection and who are to have genito-urinary surgery or instrumentation under general anaesthesia. In the case of Obstetric and Gynaecological Procedures and Gastrointestinal Procedures - routine prophylaxis is recommended only for patients with prosthetic heart valves.		Initially: 1 g ‘Amoxil’ IV or IM with 120 mg gentamicin IV or IM, immediately before induction. Followed by (6 hours later): 500 mg ‘Amoxil’ orally or IV or IM according to clinical condition.		See Notes 2, 3 and 4 above.
Surgery or Instrumentation of the Upper Respiratory Tract	Patients other than those with prosthetic heart valves.	1 g ‘Amoxil’ IV or IM immediately before induction; 500 mg ‘Amoxil’ IV or IM 6 hours later.	50 mg amoxicillin/kg body weight given as a single dose one hour preceding the surgical procedure	See Note 2 above. Note 5. The second dose of ‘Amoxil’ may be administered orally as ‘Amoxil’ Syrup SF/DF.
	Patients with prosthetic heart valves.	Initially: 1 g ‘Amoxil’ IV or IM with 120 mg gentamicin IV or IM, immediately before induction; followed by (6 hours later) 500 mg ‘Amoxil’ IV or IM.	50 mg amoxicillin/kg body weight given as a single dose one hour preceding the surgical procedure	See Notes 2, 3, 4 and 5 above.

Administration:

Oral.

Treatment should be continued for 2 to 3 days following the disappearance of symptoms. It is recommended that at least 10 days treatment be given for any infection caused by beta-haemolytic streptococci in order to achieve eradictaion of the organism.

4.3. Contra-Indications

Amoxil is a penicillin and should not be given to penicillin-hypersensitive patients. Attention should be paid to possible cross-sensitivity with other beta-lactam antibiotics eg. cephalosporins.

4.4 Special warnings and precautions for use

Before initiating therapy with amoxicillin, careful enquiry should be made concerning previous hypersensitivity reactions to penicillins, cephalosporins. Serious and occasionally fatal hypersensitivity (anaphylactoid) reactions have been reported in patients on penicillin therapy. These reactions are more likely to occur in individuals with a history of hypersensitivity to beta-lactam antibiotics (see 4.3).

Erythematous (morbilliform) rashes have been associated with glandular fever in patients receiving amoxicillin.

Prolonged use may also occasionally result in overgrowth of non-susceptible organisms.

In patients with reduced urine output, crystalluria has been observed very rarely, predominantly with parenteral therapy. During the administration of high doses of amoxicillin, it is advisable to maintain adequate fluid intake and urinary output in order to reduce the possibility of amoxicillin crystalluria (see Section 4.9 Overdose).

In patients with renal impairment, the rate of excretion of amoxicillin will be reduced depending on the degree of impairment and it may be necessary to reduce the total daily unit amoxicillin dosage accordingly (see section 4.2).

Abnormal prolongation of prothrombin time (increased INR) has been reported rarely in patients receiving amoxicillin and oral anticoagulants. Appropriate monitoring should be undertaken when anticoagulants are prescribed concomitantly. Adjustments in the dose of oral anticoagulants may be necessary to maintain the desired level of anticoagulation (see sections 4.5 and 4.8).

Precaution should be taken in premature children and during the neonatal period: renal, hepatic and haematological functions should be monitored.

Amoxil Paediatric Suspension contains 4 mg of aspartame (E951) per 1.25 ml dose, a source of phenylalanine. This medicine should be used with caution in patients with phenylketonuria.

4.5 Interaction with other Medicinal Products and other Forms of Interaction

Probenecid decreases the renal tubular secretion of amoxicillin. Concurrent use with Amoxil may result in increased and prolonged blood levels of amoxicillin.

In common with other antibiotics, amoxicillin may affect the gut flora, leading to lower oestrogen reabsorption and reduced efficacy of combined oral contraceptives.

Concurrent administration of allopurinol during treatment with amoxicillin can increase the likelihood of allergic skin reactions.

In the literature there are rare cases of increased international normalised ratio in patients maintained on acenocoumarol or warfarin and prescribed a course of amoxicillin. If co-administration is necessary, the prothrombin time or international normalised ratio should be carefully monitored with the addition or withdrawal of amoxicillin (see sections 4.4 and 4.8).

It is recommended that when testing for the presence of glucose in urine during amoxicillin treatment, enzymatic glucose oxidase methods should be used. Due to the high urinary concentrations of amoxicillin, false positive readings are common with chemical methods.

4.6. Pregnancy and Lactation

Use in pregnancy:

Animal studies with Amoxil have shown no teratogenic effects. The product has been in extensive clinical use since 1972 and its suitability in human pregnancy has been well documented in clinical studies. When antibiotic therapy is required during pregnancy, Amoxil may be considered appropriate when the potential benefits outweigh the potential risks associated with treatment.

Use in lactation:

Amoxycillin may be given during lactation. With the exception of the risk of sensitisation associated with the excretion of trace quantities of amoxycillin in breast milk, there are no known detrimental effects for the breast-fed infant.

4.7. Effects on Ability to Drive and Use Machines

Adverse effects on the ability to drive or operate machinery have not been observed.

4.8 Undesirable Effects

The following convention has been utilised for the classification of undesirable effects:-

Very common ( >1/10), common ( >1/100, <1/10), uncommon ( >1/1000,<1/100), rare ( >1/10,000, <1/1000), very rare (<1/10,000)

The majority of side effects listed below are not unique to amoxicillin and may occur when using other penicillins.

Unless otherwise stated, the frequency of adverse events has been derived from more than 30 years of post-marketing reports.

Infections and infestations

Very Rare:    Mucocutaneous candidiasis

Blood and lymphatic system disorders

Very rare:    Reversible leucopenia (including severe neutropenia or

agranulocytosis), reversible thrombocytopenia and haemolytic anaemia.

Prolongation of bleeding time and prothrombin time (see section 4.4 - Special Warnings and Precautions for Use

Immune system disorders

Very rare:    As with other antibiotics, severe allergic reactions, including

angioneurotic oedema, anaphylaxis (see Section 4.4 - Special Warnings    and Precautions for Use), serum sickness and

hypersensitivity vasculitis.

If a hypersensitivity reaction is reported, the treatment must be discontinued. (See also Skin and subcutaneous tissue disorders).

Nervous system disorders

Very rare:    Hyperkinesia, dizziness and convulsions. Convulsions may occur in

patients with impaired renal function or in those receiving high

doses.

Gastrointestinal disorders

Clinical Trial Data

*Common:    Diarrhoea and nausea.

*Uncommon: Vomiting.

Post-marketing Data

Very rare:    Antibiotic associated colitis (including pseudomembraneous colitis

and haemorrhagic colitis).

Black hairy tongue

Superficial tooth discolouration has been reported in children. Good oral hygiene may help to prevent tooth discolouration as it can usually be removed by brushing.

Hepato-biliary disorders

Hepatitis and cholestatic jaundice. A moderate rise in AST and/or

The significance of a rise in AST and/or ALT is unclear.

Skin and subcutaneous tissue disorders

Clinical Trial Data * Common:    Skin rash

♦Uncommon: Urticaria and pruritus

Post-marketing Data

Very rare:    Skin reactions such as erythema multiforme, Stevens-Johnson

syndrome,    toxic epidermal necrolysis, bullous and exfoliative dermatitis

and acute    generalised exanthematous pustulosis (AGEP)

(See also Immune system disorders).

Renal and urinary tract disorders Very rare:    Interstitial nephritis.

Very rare:    Crystalluria (see Section 4.9 Overdose).

*The incidence of these AEs was derived from clinical    studies involving a total of

approximately 6,000 adult and paediatric patients taking amoxicillin.

4.9. Overdose

Gastrointestinal effects such as nausea, vomiting and diarrhoea may be evident and should be treated symptomatically with attention to the water/electrolyte balance. Amoxycillin crystalluria, in some cases leading to renal failure, has been observed (see Section 4.4 Special warnings and special precautions for use).

Amoxycillin may be removed from the circulation by haemodialysis.

5. PHARMACOLOGICAL PROPERTIES 5.1. Pharmacodynamic Properties

Amoxil is a broad spectrum antibiotic.

It is rapidly bactericidal and possesses the safety profile of a penicillin.

The wide range of organisms sensitive to the bactericidal action of Amoxil include:

Aerobes:

Gram-positive Streptococcus faecalis Streptococcus pneumoniae

Gram-negative Haemophilus influenzae Escherichia coli

Streptococcus pyogenes Streptococcus viridans Staphylococcus aureus (penicillin-sensitive strains only)

Corynebacterium species Bacillus anthracis Listeria monocytogenes

Anaerobes: Clostridium species

5.2 Pharmacokinetic Properties

Amoxil is well absorbed by the oral and parenteral routes. Oral administration, usually at convenient t.d.s. dosage, produces high serum levels independent of the time at which food is taken. Amoxil gives good penetration into bronchial secretions and high urinary concentrations of unchanged antibiotic.

In preterm infants with gestational age 26-33 weeks, the total body clearance after intravenous dosing of amoxicillin, day 3 of life, ranged between 0.75 - 2 ml/min, very similar to the inuline clearance (GFR) in this population. Following oral administration, the absorption pattern and the bioavailability of amoxicillin in small children may be different to that of adults. Consequently, due to the decreased CL, the exposure is expected to be elevated in this group of patients, although this increase in exposure may in part be diminished by decreased bioavailability when given orally.

5.3. Pre-clinical Safety Data

Not applicable.

6 PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Amoxil Paediatric Suspension

The powder contains xanthan gum (E415), sodium benzoate (E211), sodium carboxymethylcellulose (E466), silica hydrophobic colloidal, magnesium stearate (E572), peach, strawberry and lemon flavours and aspartame (E951).

Incompatibilities

None known.

6.3    Shelf life

36 months (once reconstituted: 14 days)

6.4    Special    precautions for storage

Prior to use, Amoxil Paediatric Suspension should be stored in a dry place.

Once dispensed, Amoxil Paediatric Suspension should be stored at 25°C or below and used within 14 days.

6.5    Nature    and contents of container

Amoxil Paediatric Suspension: 125 mg per 1.25 ml: Original Pack of 20 ml with syringe and Patient Information Leaflet.

6.6    Special    precautions for disposal

•    Check cap seal is intact before use.

•    Invert and shake bottle to loosen powder.

•    Fill the bottle with water to just below the mark on the bottle label.

•    Invert and shake well, then top up with water to the mark. Invert and shake again.

•    Shake well before taking each dose.

Administrative Data

7. Marketing Authorisation Holder

Beecham Group plc Great West Road Brentford

Middlesex TW8 9GS Trading as:

GlaxoSmithKline UK, Stockley Park West, Uxbridge, Middlesex UB11 1BT or

Bencard or SmithKline Beecham Pharmaceuticals, Mundells, Welwyn Garden City,